论文部分内容阅读
目的分析白蛋白结合型紫杉醇与紫杉醇脂质体治疗复发性卵巢癌近期疗效及对Twist蛋白和血管内皮生长因子(VEGF)表达的影响。方法回顾性分析2013年4月至2014年3月本院收治的76例复发性卵巢癌患者的临床资料。按照治疗方法不同将其分为观察组和对照组,每组各38例。观察组患者予以白蛋白结合型紫杉醇联合奈达铂治疗,对照组患者予以紫杉醇脂质体联合奈达铂治疗。分析两组患者癌抗原125(CA125)、肿瘤病灶的变化情况,不良反应的差异以及Twist和VEGF的表达。结果观察组患者CA125下降和病灶缩小的有效率明显高于对照组(P<0.05)。观察组患者各不良反应发生率均明显低于对照组(P<0.05)。观察组患者Twist、VEGF阳性表达率均明显高于对照组(P<0.05)。Twist和VEGF阳性表达率和淋巴结是否转移呈正相关(P<0.05),而Twist和VEGF阳性表达率和患者的年龄以及肿瘤直径无关(P>0.05)。结论白蛋白结合型紫杉醇治疗复发性卵巢癌近期疗效优于紫杉醇脂质体,患者的耐受性较好;同时,Twist和VEGF在复发性卵巢癌近期发生发展中有重要作用。
Objective To analyze the effect of albumin-bound paclitaxel and paclitaxel liposomes on the treatment of recurrent ovarian cancer and its effect on the expression of Twist protein and vascular endothelial growth factor (VEGF). Methods The clinical data of 76 patients with recurrent ovarian cancer admitted to our hospital from April 2013 to March 2014 were retrospectively analyzed. In accordance with the different treatment methods were divided into observation group and control group, 38 cases in each group. Patients in the observation group were treated with albumin-bound paclitaxel combined with nedaplatin, and patients in the control group were treated with paclitaxel liposome combined with nedaplatin. Analysis of two groups of patients with cancer antigen 125 (CA125), tumor lesions changes, differences in adverse reactions and Twist and VEGF expression. Results The effective rate of CA125 decrease and lesion in observation group was significantly higher than that in control group (P <0.05). The incidence of adverse reactions in observation group was significantly lower than that in control group (P <0.05). The positive expression rates of Twist and VEGF in the observation group were significantly higher than those in the control group (P <0.05). The positive rate of Twist and VEGF was positively correlated with the lymph node metastasis (P <0.05), while the positive rate of Twist and VEGF was not related with the age and tumor diameter (P> 0.05). Conclusions The efficacy of albumin-bound paclitaxel in the treatment of recurrent ovarian cancer is better than that of paclitaxel liposome in the short term, and the patients are well tolerated. Meanwhile, Twist and VEGF play an important role in the recent occurrence and development of recurrent ovarian cancer.